Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1628 1629
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18555104 | RETINOL FORMULATION (I) | Non-Final OA | DSM IP ASSETS B.V. |
| 17442968 | Tip60 Inhibitors and Methods of Use for Cardiovascular Disease | Non-Final OA | The Medical College of Wisconsin, Inc. |
| 18179196 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | Final Rejection | ANTECIP BIOVENTURES II LLC |
| 17571110 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | Non-Final OA | ANTECIP BIOVENTURES II LLC |
| 17541461 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | Final Rejection | ANTECIP BIOVENTURES II LLC |
| 18570552 | ORAL FORMULATION CONTAINING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID | Non-Final OA | LG CHEM, LTD. |
| 17928765 | USE OF 2-HOBA TO TREAT ATHEROSCLEROSIS | Final Rejection | Vanderbilt University |
| 18269390 | CLATHRATE IN WHICH EQUOL IS INCLUDED IN CYCLODEXTRIN, EQUOL-ABSORBENT COMPOSITION CONTAINING SAID CLATHRATE, AND PRODUCTION METHOD THEREFOR | Final Rejection | DAICEL CORPORATION |
| 18426706 | ANTICANCER DRUG-CONTAINING PLANT VIRUS PARTICLES | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 17397911 | AMELIORATING AGENT FOR FEMALE-SPECIFIC PHYSICAL AND/OR MENTAL UNPLEASANT SYMPTOM | Non-Final OA | OTSUKA PHARMACEUTICAL CO., LTD. |
| 18571412 | INJECTABLE, BIODEGRADABLE AND REMOVABLE POLYMER BASED DRUG SUSPENSION FOR ULTRA-LONG-ACTING DRUG DELIVERY | Non-Final OA | The University of North Carolina at Chapel Hill |
| 18556564 | PROTEASE INHIBITORS AND METHODS OF USE | Non-Final OA | The Cleveland Clinic Foundation |
| 18553480 | FORMULATION | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 19026003 | COMPOSITIONS FOR TREATING GENITAL HERPES AND METHODS OF THEIR USE | Non-Final OA | PAGARI LIFE SCIENCE CORP |
| 18548641 | METHOD FOR CONTROLLING HARMFUL ARTHROPODS OR HARMFUL NEMATODES USING ZOANTHAMINE | Final Rejection | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 18018924 | COMPOSITIONS AND METHODS FOR DELIVERING PHARMACEUTICAL AGENTS | Final Rejection | Arizona Board of Regents on Behalf of the University of Arizona |
| 18138058 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Non-Final OA | Georgetown University |
| 18824121 | TREATMENT OF CHRONIC COUGH, BREATHLESSNESS AND DYSPNEA | Non-Final OA | Trevi Therapeutics, Inc. |
| 17910613 | METABOLITES RELEASED FROM APOPTOTIC CELLS ACT AS NOVEL TISSUE MESSENGERS | Non-Final OA | University of Virginia Patent Foundation |
| 18138375 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | Final Rejection | Albireo AB |
| 18417748 | METHOD OF INITIATING AND ESCALATING SOTALOL HYDROCHLORIDE DOSING | Non-Final OA | AltaThera Pharmaceuticals LLC |
| 18324703 | METHODS OF INTRAVENOUSLY ADMINISTERING SOTALOL | Non-Final OA | AltaThera Pharmaceuticals LLC |
| 18126561 | METHODS OF ADMINISTERING SOTALOL HYDROCHLORIDE | Final Rejection | AltaThera Pharmaceuticals LLC |
| 17861226 | METHOD OF INITIATING AND ESCALATING SOTALOL HYDROCHLORIDE DOSING | Final Rejection | AltaThera Pharmaceuticals LLC |
| 18367416 | SUSTAINED-RELEASE FORMULATIONS OF COLCHICINE AND METHODS OF USING SAME | Final Rejection | MURRAY AND POOLE ENTERPRISES LTD |
| 17385734 | COLCHICINE SALICYLATE DERIVATIVES AND METHODS OF TREATMENT | Non-Final OA | Murray and Poole Enterprises, LTD. |
| 18568193 | USE OF COMPOUNDS IN INHIBITING OR KILLING MITES AND TREATING XEROPHTHALMIA | Non-Final OA | Precious Future (Guangdong) Biotechnologies Ltd. |
| 18567468 | PARP7 INHIBITOR AND USE THEREOF | Non-Final OA | NOVOSTAR PHARMACEUTICALS, LTD. |
| 18527676 | COMPOSITION FOR TREATING ACUTE BRAIN INJURY OR NEURODEGENERATIVE DISEASE, METHOD OF MAKING, AND USE THEREOF | Non-Final OA | MOREHOUSE SCHOOL OF MEDICINE |
| 18565721 | MINERALOCORTICOID RECEPTOR ANTAGONISTS FOR THE PREVENTION AND/OR TREATMENT OF A CORONAVIRUS INFECTION | Non-Final OA | Imaginatives Group Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy